Can Intermittent Fasting Help Fight Cancer? What the Research Says

Research shows intermittent fasting may reduce cancer risk by lowering inflammation, regulating insulin, and triggering autophagy — the body's cellular cleanup process. While fasting is not a cancer treatment, emerging studies suggest it may make cancer cells more vulnerable while protecting healthy cells.

Why This Matters

Cancer is one of the leading causes of death worldwide, and scientists are urgently looking for lifestyle-based strategies that can reduce risk or improve treatment outcomes. Intermittent fasting has moved from a weight-loss tool to a serious subject of cancer biology research in the past decade. Understanding what the evidence actually says — and what it does not — can help you make informed decisions about your health.

What Science Says About Fasting and Cancer

Autophagy: The Body's Internal Housekeeping

One of the most discussed mechanisms linking fasting and cancer is autophagy. During a fasting period, your body activates this self-cleaning process in which damaged or dysfunctional cells are broken down and recycled. Yoshinori Ohsumi won the 2016 Nobel Prize in Physiology for mapping autophagy — and research since then has explored how it relates to cancer prevention.

When autophagy functions correctly, it may prevent the buildup of damaged DNA and dysfunctional proteins that can eventually trigger tumor formation. Studies published in journals such as Nature Reviews Cancer suggest that impaired autophagy is commonly observed in early-stage cancer development, hinting that keeping this process active through regular fasting windows may have a protective role.

Insulin, IGF-1, and Cancer Cell Fuel

Cancer cells are often described as metabolically greedy — they consume glucose at a far higher rate than healthy cells. This is known as the Warburg effect. High levels of insulin and insulin-like growth factor 1 (IGF-1) in the bloodstream act as fuel for this rapid cancer cell growth.

Intermittent fasting consistently lowers fasting insulin levels and reduces circulating IGF-1. A 2019 study in JAMA Oncology found that postmenopausal women who fasted for fewer than 13 hours per night had a 36% higher risk of breast cancer recurrence compared to those who fasted longer. Longer nightly fasting was associated with lower IGF-1 levels and better outcomes.

Inflammation as a Cancer Driver

Chronic low-grade inflammation creates an environment in which cancer cells can take root and grow. Intermittent fasting has been shown in multiple studies to reduce key inflammatory markers including C-reactive protein (CRP) and interleukin-6 (IL-6). By reducing this background inflammation, fasting may help the immune system maintain better surveillance against rogue cells.

Fasting During Chemotherapy: A Promising but Cautious Area

Some oncology researchers have explored whether short-term fasting before and after chemotherapy might protect healthy cells while making cancer cells more susceptible to treatment. A pilot study at the University of Southern California led by Dr. Valter Longo showed that patients who fasted around chemotherapy sessions reported fewer side effects and some showed better treatment response. This area remains experimental and should never be pursued without close medical supervision.

Practical Tips

• Aim for at least 12–13 hours of nightly fasting. This is the minimum threshold suggested by breast cancer recurrence research and is achievable for most people by simply not eating after dinner.
• Do not eat right before bed. Eating close to sleep disrupts metabolic repair processes that happen during the overnight fast.
• Prioritize whole, anti-inflammatory foods during your eating window. Fasting benefits are amplified when your meals are built around vegetables, legumes, fish, and healthy fats — not processed foods.
• If you are currently receiving cancer treatment, always consult your oncologist before starting any fasting protocol. Fasting during treatment can affect medication absorption, energy levels, and nutritional status in ways that require medical oversight.
• Do not use fasting as a substitute for medical care. The research is promising but preliminary. Fasting may support cancer prevention and treatment — it is not a replacement for surgery, chemotherapy, immunotherapy, or other evidence-based treatments.

Want the Full Guide?

For the complete intermittent fasting guide, get Intermittent Fasting in Practice on Amazon — and claim 3 months free on our fasting app at fastinginpractice.com/redeem

Frequently Asked Questions

Does intermittent fasting kill cancer cells?

Fasting does not directly kill cancer cells. However, by lowering insulin and IGF-1 levels and activating autophagy, fasting may create conditions that are less favorable for cancer cell growth and may enhance the effectiveness of some cancer treatments. Research in this area is ongoing.

Can fasting prevent cancer?

No fasting protocol can guarantee cancer prevention. However, population studies and laboratory research suggest that regular fasting may lower the risk of certain cancers — particularly those driven by high insulin levels and chronic inflammation, such as breast, colorectal, and prostate cancers.

Is it safe to fast during chemotherapy?

Short-term fasting around chemotherapy cycles has shown promise in early studies, with some patients experiencing fewer side effects. However, this must only be done under the direct supervision of an oncologist. Cancer patients often have increased nutritional needs and fasting without guidance can be harmful.

How long should I fast to get cancer-protective benefits?

Current evidence suggests that consistently fasting for at least 13 hours overnight — for example, finishing dinner by 7 p.m. and not eating until 8 a.m. — is associated with meaningful metabolic benefits linked to reduced cancer risk. Longer fasting windows such as 16:8 may provide additional benefits but are not yet proven to offer proportionally greater cancer protection.